Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M L Rothenberg

Showing results (31-40 of 62) with videos related to

Pageof 7
Sort By:
Cancer|August 1, 1996
A rationale for expanding the endpoints for clinical trials in advanced pancreatic carcinomaM L Rothenberg, J L Abbruzzese, M Moore, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 6, 2009
Incidence and evolution of oxaliplatin-induced peripheral sensory neuropathy in diabetic patients with colorectal cancer: a pooled analysis of three phase III studiesR K Ramanathan, M L Rothenberg, A de Gramont, et al.
Cancer Treatment and Research|January 1, 1989
Mechanisms of resistance to cisplatin and alkylating agentsT C Hamilton, G M Lai, M L Rothenberg, et al.
Cancer Chemotherapy and Biological Response Modifiers|January 1, 1994
New anticancer agentsG R Weiss, H A Burris, J R Eckardt, et al.
Blood|September 1, 1989
Expression of the mdr-1/P-170 gene in patients with acute lymphoblastic leukemiaM L Rothenberg, L A Mickley, D E Cole, et al.
Clinical Pharmacology and Therapeutics|February 14, 2015
The role of nonrandomized trials in the evaluation of oncology drugsR Simon, G M Blumenthal, M L Rothenberg, et al.
Cancer Chemotherapy and Biological Response Modifiers|May 9, 2000
New anticancer agentsC Britten, L Hammond, M Hidalgo, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 2, 2002
A phase II study of irinotecan with 5-fluorouracil and leucovorin in patients with previously untreated gastric adenocarcinomaC D Blanke, D G Haller, A B Benson, et al.
Cancer|November 7, 1998
Dose intensive combination platinum and cyclophosphamide in the treatment of patients with advanced untreated epithelial ovarian cancerJ D Shapiro, M L Rothenberg, G A Sarosy, et al.
Annals of the New York Academy of Sciences|January 31, 2004
Clinical studies in patients with solid tumors using a second-generation antisense oligonucleotide (GEM 231) targeted against protein kinase A type IS Mani, S Goel, M Nesterova, et al.
Pageof 7

Showing results (31-40 of 62) with videos related to

Sort By:
Pageof 7
Cancer|August 1, 1996
A rationale for expanding the endpoints for clinical trials in advanced pancreatic carcinomaM L Rothenberg, J L Abbruzzese, M Moore, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 6, 2009
Incidence and evolution of oxaliplatin-induced peripheral sensory neuropathy in diabetic patients with colorectal cancer: a pooled analysis of three phase III studiesR K Ramanathan, M L Rothenberg, A de Gramont, et al.
Cancer Treatment and Research|January 1, 1989
Mechanisms of resistance to cisplatin and alkylating agentsT C Hamilton, G M Lai, M L Rothenberg, et al.
Cancer Chemotherapy and Biological Response Modifiers|January 1, 1994
New anticancer agentsG R Weiss, H A Burris, J R Eckardt, et al.
Blood|September 1, 1989
Expression of the mdr-1/P-170 gene in patients with acute lymphoblastic leukemiaM L Rothenberg, L A Mickley, D E Cole, et al.
Clinical Pharmacology and Therapeutics|February 14, 2015
The role of nonrandomized trials in the evaluation of oncology drugsR Simon, G M Blumenthal, M L Rothenberg, et al.
Cancer Chemotherapy and Biological Response Modifiers|May 9, 2000
New anticancer agentsC Britten, L Hammond, M Hidalgo, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 2, 2002
A phase II study of irinotecan with 5-fluorouracil and leucovorin in patients with previously untreated gastric adenocarcinomaC D Blanke, D G Haller, A B Benson, et al.
Cancer|November 7, 1998
Dose intensive combination platinum and cyclophosphamide in the treatment of patients with advanced untreated epithelial ovarian cancerJ D Shapiro, M L Rothenberg, G A Sarosy, et al.
Annals of the New York Academy of Sciences|January 31, 2004
Clinical studies in patients with solid tumors using a second-generation antisense oligonucleotide (GEM 231) targeted against protein kinase A type IS Mani, S Goel, M Nesterova, et al.
Pageof 7